June 19, 2017 07:51 AM EDT

Novartis wins another biosimilar round with an OK for its Rituxan copycat

John Carroll

Editor & Founder

Novartis just racked up its fourth new biosimilar approval in Europe, this time gaining a thumbs up for its knockoff of Roche megablockbuster Rituxan …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis wins another biosimilar round with an OK for its Rituxan copycat

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

GSK defiant against vaccine challenges, will prioritize other growth areas

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

Updated: Novo Nordisk sees growth slowing this year, plans CagriSema filing for 2026

EyePoint shares more mid-stage data for therapy trying to compete with Regeneron's Eylea

Bristol Myers, Kyowa Kirin disclose layoffs

No­var­tis wins an­oth­er biosim­i­lar round with an OK for its Rit­ux­an copy­cat

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Novartis wins another biosimilar round with an OK for its Rituxan copycat